Document Detail

Oncolytic measles virus strains as novel anticancer agents.
MedLine Citation:
PMID:  23289598     Owner:  NLM     Status:  Publisher    
Introduction: Replication-competent oncolytic measles virus (MV) strains preferentially infect and destroy a wide variety of cancer tissues. Clinical translation of engineered attenuated MV vaccine derivatives is demonstrating the therapeutic potential and negligible pathogenicity of these strains in humans. Areas covered: The present review summarizes the mechanisms of MV tumor selectivity and cytopathic activity as well as the current data on the oncolytic efficacy and preclinical testing of MV strains. Investigational strategies to reprogram MV selectivity, escape antiviral immunity and modulate the immune system to enhance viral delivery and tumor oncolysis are also discussed. Expert opinion: Clinical viral kinetic data derived from noninvasive monitoring of reporter transgene expression will guide future protocols to enhance oncolytic MV efficacy. Anti-measles immunity is a major challenge of measles-based therapeutics and various strategies are being investigated to modulate immunity. These include the combination of MV therapy with immunosuppressive drugs, such as cyclophosphamide, the use of cell carriers and the introduction of immunomodulatory transgenes and wild-type virulence genes. Available MV retargeting technologies can address safety considerations that may arise as more potent oncolytic MV vectors are being developed.
Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Related Documents :
23762578 - Seroprevalence of fowl pox antibody in indigenous chickens in jos north and south counc...
24334588 - A patient who survived primary seasonal influenza viral pneumonia: histologic findings ...
24747008 - Development of a reverse transcription loop-mediated isothermal amplification assay for...
23382108 - Cytokine profiles in children with primary epstein-barr virus infection.
16404988 - Detection of antibodies to the nonstructural protein (ns1) of avian influenza viruses a...
1738818 - Interferon-gamma production by african swine fever virus-specific lymphocytes.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-6
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  -     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Albert Einstein College of Medicine, Jacobi Medical Center, Department of Internal Medicine , Bronx, NY , USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hope and cardiovascular health-promoting behaviour: Education alone is not enough.
Next Document:  Accuracy and Reliability of Methods to Measure Marginal Adaptation of Crowns and FDPs: A Literature ...